Literature DB >> 15719273

Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases.

Lucinda Aguirre-Cruz1, Jean-Luc Charuel, Antoine F Carpentier, Baya Benyahia, Jean-Yves Delattre, Lucile Musset.   

Abstract

About half of the patients with paraneoplastic diseases develop an immune response against neuronal antigens expressed by both the tumor and the nervous system. In 31 patients with anti-Hu antibodies and 19 patients with anti-Yo antibodies, we searched for the presence of additional non-neuronal auto-antibodies and further studied whether the presence of such auto-antibodies was correlated with a specific oncological or neurological presentation. Positive antinuclear antibodies (ANA) were found at a titer of 1:40 or above in 48% patients with anti-Hu antibodies, and in 37% patients with anti-Yo antibodies. Anti-cytoplasmic antibodies were also detected in 42% patients with anti-Yo antibodies. No specific correlation between the presence of non-neuronal auto-antibodies and clinical characteristics of the patients could be identified. In particular, neither the type of underlying cancer, the overall survival, the tumor response to treatment, nor the neurological presentation were related to the serological status.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15719273     DOI: 10.1007/s11060-004-4536-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  7 in total

1.  Systemic lupus erythematosus with anti-Hu antibodies and polyradiculoneuropathy.

Authors:  A F Carpentier; B Chassande; Z Amoura; B Benyahia; J C Piette; J Y Delattre
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

Review 2.  Paraneoplastic syndromes of the nervous system.

Authors:  J B Posner; J O Dalmau
Journal:  Clin Chem Lab Med       Date:  2000-02       Impact factor: 3.694

3.  Range of antinuclear antibodies in "healthy" individuals.

Authors:  E M Tan; T E Feltkamp; J S Smolen; B Butcher; R Dawkins; M J Fritzler; T Gordon; J A Hardin; J R Kalden; R G Lahita; R N Maini; J S McDougal; N F Rothfield; R J Smeenk; Y Takasaki; A Wiik; M R Wilson; J A Koziol
Journal:  Arthritis Rheum       Date:  1997-09

4.  Antinuclear antibodies as potential markers of lung cancer.

Authors:  F Fernández-Madrid; P J VandeVord; X Yang; R L Karvonen; P M Simpson; M J Kraut; J L Granda; J E Tomkiel
Journal:  Clin Cancer Res       Date:  1999-06       Impact factor: 12.531

5.  Systemic and anti-neuronal auto-antibodies in patients with paraneoplastic neurological disease.

Authors:  J W Moll; H Hooijkaas; B C van Goorbergh; L G Roos; S C Henzen-Logmans; C J Vecht
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

6.  Paraneoplastic antineuronal antibodies in patients with systemic autoimmune diseases.

Authors:  B Benyahia; Z Amoura; A Rousseau; C Le Clanche; A Carpentier; J C Piette; J Y Delattre
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

7.  Immune complexes in ovarian cancer: association between IgM class complexes and antinuclear autoantibodies in ascitic fluid.

Authors:  P A Silburn; J C Neil; S K Khoo; B Daunter; R Hill; R J Collins; E V Mackay
Journal:  Int Arch Allergy Appl Immunol       Date:  1984
  7 in total
  3 in total

1.  Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report.

Authors:  Katherina Bernadette Sreter; Blazenka Barisic; Marija Barisic Kutija; Suzana Kukulj; Miroslav Samarzija
Journal:  Mol Clin Oncol       Date:  2017-05-08

2.  Immune response in lung cancer mouse model mimics human anti-Hu reactivity.

Authors:  Meleeneh Kazarian; Joaquim Calbo; Natalie Proost; Catherine L Carpenter; Anton Berns; Ite A Laird-Offringa
Journal:  J Neuroimmunol       Date:  2009-09-17       Impact factor: 3.478

Review 3.  Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.

Authors:  Meleeneh Kazarian; Ite A Laird-Offringa
Journal:  Mol Cancer       Date:  2011-03-30       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.